GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

IPL344   Click here for help

GtoPdb Ligand ID: 13268

Synonyms: IPL-344
Compound class: Peptide
Comment: IPL344 is a lead candidate for the treatment of ALS. It is a heptapeptide that acts to reactivate the PI3K-Akt pathway that is impaired in ALS motor neurons and muscles. IPL344 is administered intravenously. An oral Akt activator for ALS (IPL699) is included in Immunity Pharma's preclinical development pipeline.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)O)N
Isomeric SMILES CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)O)N
InChI InChI=1S/C41H61N7O9/c1-24(2)21-28(42)37(52)47-19-7-11-33(47)40(55)46-18-6-10-32(46)36(51)43-29(22-25(3)4)38(53)45-17-5-9-31(45)35(50)44-30(23-26-13-15-27(49)16-14-26)39(54)48-20-8-12-34(48)41(56)57/h13-16,24-25,28-34,49H,5-12,17-23,42H2,1-4H3,(H,43,51)(H,44,50)(H,56,57)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
InChI Key AGUSSGJBWOOHRG-NXBWRCJVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Immunity Pharma are developing IPL344 as an ALS therapeutic, however both clinicaltrials.gov registered studies were marked as 'suspended' when reviewed in March 2024. The suspension was noted as being the result of IPL344 supply issues. The FDA designated IPL344 as an orphan drug for ALS in mid 2019.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03652805 A Study of IPL344 in the Treatment of ALS Patients Phase 1/Phase 2 Interventional Immunity Pharma Ltd.
NCT03755167 A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV Phase 2 Interventional Immunity Pharma Ltd.